Founded in 2026 and headquartered at Biopôle’s campus in Lausanne, CHD is a medtech and e-health service operator advancing maternal–fetal health through an innovative healthcare-certified e-textile belt designed for real-life monitoring conditions. Comfortable, washable and easy to use, the device simultaneously captures fetal movements and electrocardiogram (ECG) readings and maternal contractions and ECG readings without the need for gel-based sensors or clinical installation by a nurse. By covering the full maternal abdomen and using advanced dry-sensor technology, CHD’s solution generates higher-quality signals and enables more accurate diagnostics outside traditional hospital settings.
More than a remote monitoring tool, CHD’s technology supports predictive medicine through machine learning-based health indicators that help identify compromised fetal well-being and risks of preterm delivery. By enabling continuous monitoring in everyday environments, the device also improves patient adherence and quality of life during pregnancy.
Through the Vanguard Accelerator, CHD aims to strengthen its R&D collaborations with research centres, hospitals and clinics while advancing its fundraising and product validation strategy. ‘We were looking for an incubator that provides more than infrastructure – one that offers real support, coaching and integration into one of the leading healthcare ecosystems in Europe,’ explains Laurent Vandebrouck, CEO of CHD. ‘This incubator stood out for its location, depth of expertise and network. We applied to four programmes; Biopôle chose us, and we chose Biopôle.’
Being based at Biopôle further reinforces CHD’s ambition to integrate its remote patient monitoring solution into the Swiss healthcare system. In particular, the proximity to the Lausanne University Hospital (CHUV), which has recently joined CHD’s Scientific Committee, creates valuable opportunities for clinical collaboration and validation at a crucial stage of development.
Ambitious roadmap
Contacted by Startupticker.ch, CHD’s CEO Laurent Vanderbrouck, said that the femtech company has signed an agreement to access a large number of fetal ECGs and ECGs of pregnant women, which will enable the company to train its predictive algorithm in the coming months. He added that the launch of the simplified consumer version of the MONI2 fetal belt and associated smartphone app is planned for next year (distributed in B2B by resellers and not by CHD), while the certified healthcare version of MONI2, intended for hospitals, clinics, and healthcare professionals, is scheduled for the end of 2028, following clinical trials in 2028.
CHD launched in January the first tranche of its Seed fundraising in January 2026 for €1 million (€2.6 million in total in Seeding, €1 million this year, €1.6 million next year), which will end in mid-2026 so that the medtech can finalize the development, testing, and validation of the pre-industrial version of its fetal belt for remote monitoring, in real-world conditions, of high-risk pregnancies at home, collecting both the ECG of the fetus and that of the pregnant woman with health indicators capable of predicting, for example, premature birth. The smartphone app and web portal for healthcare professionals will be developed in parallel.
Joining a growing digital health startup community
By joining Biopôle’s Vanguard Accelerator, CHD becomes part of a growing community of ambitious ventures committed to transforming healthcare delivery through innovation. Participants in the programme have included MoleSense, Undae Science, DigeHealth, Virtuosis, PhenomX, biped.ai, Gabi SmartCare, Impli and Neuria.
The Vanguard Accelerator is a free six-month programme, run by Biopôle SA and its partners, to help promising digital health-oriented projects supercharge their innovation and take their business strategy to the next level. The next application deadline for startups is March 3rd, 2026
(PR – ES)
From left to right: Pierre-Jean Wipff, Innovation and Partnerships Director at Biopôle SA, Laurent Vandebrouck, CEO of CHD; Dr Giusy Fiucci, COO; Professor Nicolas Sananès, CMO; Fernando Romao, CTO.
